HCA:NYE-HCA Holdings Inc. (USD)

EQUITY | Medical Care Facilities | New York Stock Exchange

Last Closing

USD 356.36

Change

-6.76 (-1.86)%

Market Cap

USD 26.31B

Volume

1.60M

Analyst Target

USD 147.05
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

HCA Holdings Inc is a health care services company. It operates general acute care hospitals, psychiatric hospitals; and rehabilitation hospitals. It also operates freestanding surgery centers.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Medical Care Facilities

Symbol Name Price(Change) Market Cap
THC Tenet Healthcare Corporation

N/A

USD 15.89B
UHS Universal Health Services Inc

N/A

USD 15.88B
DVA DaVita HealthCare Partners Inc

N/A

USD 12.58B
EHC Encompass Health Corp

N/A

USD 9.40B
CHE Chemed Corp

N/A

USD 8.79B
NHC National HealthCare Corporatio..

N/A

USD 1.99B
AMN AMN Healthcare Services Inc

N/A

USD 1.73B
AGL agilon health Inc

N/A

USD 1.49B
BKD Brookdale Senior Living Inc

N/A

USD 1.33B
CYH Community Health Systems Inc

N/A

USD 0.76B

ETFs Containing HCA

FHI:CA CI Health Care Giants Cov.. 5.23 % 0.75 %

N/A

CAD 0.07B
FHI-B:CA CI Health Care Giants Cov.. 5.23 % 0.00 %

N/A

CAD 0.05B
ZWHC:CA BMO Covered Call Health C.. 4.84 % 0.00 %

N/A

N/A
YALL God Bless America ETF 4.46 % 0.00 %

N/A

N/A
MHG:AU Magellan Global Equities 4.24 % 0.00 %

N/A

USD 0.10B
MGE:AU 4.11 % 0.00 %

N/A

N/A
PKW Invesco BuyBack Achievers.. 3.60 % 0.62 %

N/A

USD 1.16B
XHS SPDR® S&P Health Care Se.. 2.33 % 0.35 %

N/A

USD 0.09B
RFFC RiverFront Dynamic US Fle.. 2.21 % 0.52 %

N/A

USD 0.02B
XLVE:CA Mulvihill U.S. Health Car.. 1.79 % 0.00 %

N/A

N/A
LSAF LeaderSharesTM AlphaFacto.. 1.17 % 0.75 %

N/A

USD 0.15B
ENGUS:PA BNP Paribas Easy ECPI Glo.. 1.12 % 0.00 %

N/A

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

N/A

N/A
NASH 0.00 % 0.49 %

N/A

N/A
ENG:PA BNP Paribas EASY ECPI Glo.. 0.00 % 0.00 %

N/A

USD 0.20B
XU61:F BNP Paribas Easy SICAV - .. 0.00 % 0.00 %

N/A

USD 0.24B
XU61:XETRA BNP Paribas EASY ECPI Glo.. 0.00 % 0.00 %

N/A

USD 0.27B

Market Performance

  Market Performance vs. Industry/Classification (Medical Care Facilities) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.65% 64% D 95% A
Dividend Return 0.49% 50% F 10% F
Total Return 32.14% 64% D 95% A
Trailing 12 Months  
Capital Gain 32.63% 77% C+ 92% A
Dividend Return 0.71% 38% F 8% B-
Total Return 33.34% 77% C+ 91% A-
Trailing 5 Years  
Capital Gain 180.29% 94% A 94% A
Dividend Return 7.13% 57% F 22% F
Total Return 187.42% 94% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 29.11% 86% B+ 89% A-
Dividend Return 30.04% 86% B+ 89% A-
Total Return 0.92% 38% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 36.94% 55% F 26% F
Risk Adjusted Return 81.30% 100% F 92% A
Market Capitalization 26.31B 100% F 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Care Facilities) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.50 47% 51%
Price/Book Ratio 293.44 6% 1%
Price / Cash Flow Ratio 9.93 37% 39%
Price/Free Cash Flow Ratio 9.93 37% 42%
Management Effectiveness  
Return on Equity 73.61% 94% 98%
Return on Invested Capital 21.91% 94% 90%
Return on Assets 11.47% 95% 95%
Debt to Equity Ratio -2,095.21% 100% 100%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.